Integer (NYSE:ITGR) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, August 1st. Analysts expect Integer to post earnings of $1.05 per share for the quarter. Integer has set its FY19 guidance at $4.15-4.35 EPS.Individual interested in listening to the company’s earnings conference call can do so using this link.
Integer (NYSE:ITGR) last issued its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.00 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.80 by $0.20. Integer had a return on equity of 13.37% and a net margin of 14.67%. The business had revenue of $314.70 million during the quarter, compared to analysts’ expectations of $302.29 million. During the same period in the previous year, the firm posted $0.61 earnings per share. The company’s revenue was up 7.6% on a year-over-year basis. On average, analysts expect Integer to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.
Shares of NYSE ITGR opened at $88.17 on Wednesday. Integer has a twelve month low of $67.72 and a twelve month high of $92.61. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.55 and a quick ratio of 1.49. The company has a fifty day moving average price of $82.34. The firm has a market capitalization of $2.81 billion, a PE ratio of 23.20 and a beta of 0.95.
In related news, Director James F. Hinrichs bought 3,750 shares of the stock in a transaction that occurred on Thursday, May 23rd. The stock was purchased at an average cost of $68.47 per share, with a total value of $256,762.50. Following the purchase, the director now directly owns 6,549 shares of the company’s stock, valued at approximately $448,410.03. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.24% of the company’s stock.
A number of equities research analysts have recently weighed in on the company. ValuEngine cut Virtu Financial from a “hold” rating to a “sell” rating in a research note on Tuesday, June 18th. Zacks Investment Research cut GenMark Diagnostics from a “hold” rating to a “sell” rating in a research note on Wednesday, April 24th. Finally, Argus lifted their price objective on Aqua America from $2.00 to $43.00 in a research note on Wednesday, June 5th. They noted that the move was a valuation call. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Integer has an average rating of “Hold” and a consensus price target of $72.57.
Integer Holdings Corporation operates as a medical device outsource manufacturer worldwide. It operates in two segments, Medical and Non-Medical. The company offers products for vascular, cardiac surgery, and structural heart diseases; peripheral vascular, neurovascular, urology, and oncology products; and electrophysiology, infusion therapy, and hemodialysis products.
See Also: How to identify percentage decliners
Receive News & Ratings for Integer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integer and related companies with MarketBeat.com's FREE daily email newsletter.